Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr 16;10(11):3579-3586.
doi: 10.12998/wjcc.v10.i11.3579.

Anti-nuclear matrix protein 2+ juvenile dermatomyositis with severe skin ulcer and infection: A case report and literature review

Ya-Ting Wang  1 , Yu Zhang  1 , Tao Tang  1 , Chong Luo  1 , Ming-Yue Liu  1 , Li Xu  1 , Li Wang  1 , Xue-Mei Tang  1
Affiliations
Case Reports

Anti-nuclear matrix protein 2+ juvenile dermatomyositis with severe skin ulcer and infection: A case report and literature review

Ya-Ting Wang et al. World J Clin Cases. .

Abstract

Background: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy that occurs in childhood. It is characterized by muscle weakness and a characteristic rash. Previous literature reports have rarely described JDM with severe skin ulcers and infections.

Case summary: Herein, we describe a case of a 2-year-old female patient who suffered from JDM, whose myositis-specific autoantibodies were positive for anti-nuclear matrix protein 2 antibody, with progressively worsening skin ulcers and severe infections. The patient was treated with glucocorticoids and various immunosuppressants. Nevertheless, further progression of the disease and the combination of primary disease and severe infection in the later period were fatal.

Conclusion: In children, anti-nuclear matrix protein 2+ JDM combined with skin ulcers often indicates severe disease. In such cases, personalized treatment for the primary disease and infection prevention and control are essential.

Keywords: Anti-nuclear matrix protein 2 antibody; Case report; Juvenile dermatomyositis; Skin ulcer.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Clinal examination 3, 6, and 10 mo after diagnosis. A: 3 mo, livedo reticularis; B: 6 mo, ulcers in the buttock; C and D: 10 mo, ulcers in the back (C) and left (D) shoulder.
Figure 2
Figure 2
Deepening of the ulcers after treatment (A and B).
See this image and copyright information in PMC

References

    1. Rider LG, Lidsley CB, Miller FW. Juvenile dermatomyositis. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, editors. Textbook of pediatric rheumatology, 7th ed. Philadelphia: Elsevier Saunder; 2016: 351-384.
    1. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201–2212. - PubMed
    1. Varnier GC, Pilkington CA, Wedderburn LR. Juvenile dermatomyositis: novel treatment approaches and outcomes. Curr Opin Rheumatol. 2018;30:650–654. - PubMed
    1. Poddighe D, Dauyey K. Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. Rheumatol Int. 2020;40:695–702. - PubMed
    1. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, Pachman LM NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49:300–305. - PubMed

Publication types